SCHEMBL1402835

SCHEMBL1402835

COC(=O)C=Cc1cccc(S(=O)(=O)Nc2ccccc2)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 17/20 0.71
HDAC8 Q9BY41 17/20 0.71
HDAC3 O15379 16/20 0.71
HDAC4 P56524 16/20 0.71
HDAC7 Q8WUI4 16/20 0.71
HDAC2 Q92769 16/20 0.71
HDAC10 Q969S8 16/20 0.71
HDAC11 Q96DB2 16/20 0.71
HDAC6 Q9UBN7 16/20 0.71
HDAC9 Q9UKV0 16/20 0.71
HDAC5 Q9UQL6 16/20 0.71
BRD4 O60885 1/20 0.71
ESR1 P03372 1/20 0.71
PTGS1 P23219 1/20 0.71
PDE4A P27815 1/20 0.71
PIK3CA P42336 1/20 0.71
HTR6 P50406 1/20 0.71
PDE4D Q08499 1/20 0.71
ASPH Q12797 1/20 0.71
THRB P10828 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1402831 1.00 HDAC1 (0.71) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL1403275 0.93 HDAC1 (0.73) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL1403277 0.93 HDAC1 (0.73) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL1403346 0.92 HDAC3 (0.71) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL1403347 0.92 HDAC3 (0.71) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL1402867 0.90 HDAC1 (0.74) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL1402868 0.90 HDAC1 (0.74) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL13762637 0.89 HDAC1 (0.65) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL7160879 0.89 HDAC4 (0.79) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL7160883 0.89 HDAC4 (0.79) HDAC1HDAC8HDAC3HDAC4HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1328510-B1 (E)-N-HYDROXY-3-(3-SULFAMOYL-PHENYL)-ACRYLAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE TOPOTARGET UK LTD (GB) 2013-11-20 EP disclosed
EP-2292593-A2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TopoTarget UK Limited (GB) 2011-03-09 EP disclosed
US-7557140-B2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2009-07-07 US disclosed
US-7407988-B2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2008-08-05 US disclosed
US-20080161401-A1 CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS TOPOTARGET UK LIMITED (GB) 2008-07-03 US disclosed
US-7183298-B2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2007-02-27 US disclosed
US-20070004806-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2007-01-04 US disclosed
US-20050107445-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors PROLIFIX LIMITED (GB) 2005-05-19 US disclosed
US-6888027-B2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2005-05-03 US disclosed
US-20050085515-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPO TARGET UK LIMITED, (GB) 2005-04-21 US disclosed
US-20040077726-A1 Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors SWK FUNDING LLC 2004-04-22 US disclosed
EP-1328510-A2 CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS PROLIFIX LTD. (GB) 2003-07-23 EP disclosed
WO-2002030879-A2 CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS PROLIFIX LIMITED (GB) 2002-04-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107445-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors HDAC1, HDAC11, HDAC3 HDAC1 1/4885HDAC8 4/4885HDAC3 3/4885
US-20070004806-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors HDAC1, HDAC11, HDAC3 HDAC1 1/4885HDAC8 4/4885HDAC3 3/4885
US-20080161401-A1 CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS HDAC1, HDAC11, HDAC3 HDAC1 1/4885HDAC8 4/4885HDAC3 3/4885
US-20040077726-A1 Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors HDAC1, HDAC11, HDAC2 HDAC1 1/4885HDAC8 4/4885HDAC3 5/4885
US-20050085515-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors HDAC1, HDAC11, HDAC3 HDAC1 1/4885HDAC8 4/4885HDAC3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.